fpl 67047xx has been researched along with gamma-aminobutyric acid in 5 studies
*gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system. [MeSH]
*gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system. [MeSH]
| Studies (fpl 67047xx) | Trials (fpl 67047xx) | Recent Studies (post-2010) (fpl 67047xx) | Studies (gamma-aminobutyric acid) | Trials (gamma-aminobutyric acid) | Recent Studies (post-2010) (gamma-aminobutyric acid) |
|---|---|---|---|---|---|
| 6 | 0 | 2 | 40,215 | 1,423 | 9,631 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beaton, HG; Bennion, C; Connolly, S; Cook, AR; Gensmantel, NP; Hallam, C; Hardy, K; Hitchin, B; Jackson, CG; Robinson, DH | 1 |
| Abdel-Meguid, SS; Adams, J; Bolognese, B; Cha, SS; Jones, CS; Kurdyla, JT; Lee, D; Marshall, LA; Oh, BH | 1 |
| Hamelehle, KL; Homan, R | 1 |
| Kokotos, G; Mavromoustakos, TM; Mouchlis, VD | 1 |
| Barbayianni, E; Kokotos, G; Mavromoustakos, TM; Mouchlis, VD | 1 |
1 review(s) available for fpl 67047xx and gamma-aminobutyric acid
| Article | Year |
|---|---|
The application of rational design on phospholipase A(2) inhibitors.
Topics: Bee Venoms; Benzhydryl Compounds; Catalytic Domain; Chromans; Computer-Aided Design; Diketopiperazines; Drug Design; Enzyme Inhibitors; Flavonoids; gamma-Aminobutyric Acid; Group II Phospholipases A2; Humans; Indoles; Models, Molecular; Molecular Conformation; Phenols; Phospholipase A2 Inhibitors; Phospholipases A2; Quantitative Structure-Activity Relationship; Sesquiterpenes; Sulfonamides | 2011 |
4 other study(ies) available for fpl 67047xx and gamma-aminobutyric acid
| Article | Year |
|---|---|
Discovery of new non-phospholipid inhibitors of the secretory phospholipases A2.
Topics: Animals; Benzhydryl Compounds; Binding Sites; Blood Platelets; Drug Design; gamma-Aminobutyric Acid; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Pancreas; Phospholipases A; Structure-Activity Relationship; Swine | 1994 |
High-resolution X-ray crystallography reveals precise binding interactions between human nonpancreatic secreted phospholipase A2 and a highly potent inhibitor (FPL67047XX).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzhydryl Compounds; Chemical Phenomena; Chemistry, Physical; Crystallization; Crystallography, X-Ray; Enzyme Inhibitors; gamma-Aminobutyric Acid; Humans; Hydrogen Bonding; Mice; Models, Molecular; Otitis; Phospholipases A; Phospholipases A2 | 1996 |
Phospholipase A2 relieves phosphatidylcholine inhibition of micellar cholesterol absorption and transport by human intestinal cell line Caco-2.
Topics: Benzhydryl Compounds; Caco-2 Cells; Cholesterol; Enzyme Inhibitors; gamma-Aminobutyric Acid; Glycerides; Humans; Intestinal Absorption; Intestinal Mucosa; Lysophosphatidylcholines; Micelles; Oleic Acid; Phosphatidylcholines; Phospholipases A; Phospholipases A2; Taurocholic Acid; Vitamin A | 1998 |
Design of new secreted phospholipase A2 inhibitors based on docking calculations by modifying the pharmacophore segments of the FPL67047XX inhibitor.
Topics: Benzhydryl Compounds; Catalytic Domain; Computational Biology; Computer Simulation; Computer-Aided Design; Drug Design; Enzyme Inhibitors; gamma-Aminobutyric Acid; Models, Molecular; Phospholipase A2 Inhibitors; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship | 2010 |